VEGFA and nonpapillary renal cell carcinoma: The effectiveness of trials of targeted regimens for ccRCC had revolutionized the treatment options for this disease-particularly the application of targeted vascular endothelial growth factor (VEGF) and immune checkpoint inhibitors (ICI) (5).